Explantation of patent foramen ovale closure devices: A multicenter survey

JACC: Cardiovascular Interventions

Volumn 4, Issue 5, 2011, Pages 579-585

  Verma, Swarnendra K ^a   Tobis, Jonathan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

adult congenital heart disease; device closure; explantation; patent foramen ovale; PFO closure

Indexed keywords

ADULT; AORTA ROOT; ARTICLE; CLINICAL ARTICLE; DEVICE REMOVAL; ENDOCARDITIS; FEMALE; HEART ASSIST DEVICE; HEART ATRIUM; HEART SURGERY; HUMAN; NICKEL HYPERSENSITIVITY; PATENT FORAMEN OVALE; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PROSTHESIS MATERIAL; RECURRENT DISEASE; SHUNT INFECTION; STROKE; THORAX PAIN;

CARDIAC SURGICAL PROCEDURES; DEVICE REMOVAL; EUROPE; FEMALE; FORAMEN OVALE, PATENT; HEALTH CARE SURVEYS; HEART CATHETERIZATION; HUMANS; MIDDLE AGED; PROSTHESIS DESIGN; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEPTAL OCCLUDER DEVICE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 79956278599     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2011.01.009     Document Type: Article

References (23)

1. Johansson MC, Eriksson P, Dellborg M. The significance of patent foramen ovale: a current review of associated conditions and treatment. Int J Cardiol 2009;134:17-24.
2. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 1984;59:17-20.
3. Marquand B. Heart of the Matter. Today in PT, 2009. Available at: http://news.todayinpt.com/article/20090302/TODAYINPT0103/90226004. Accessed October 20, 2010.
4. Spies C, Timmermanns I, Reissmann U, Van Essen J, Schräder R. Patent foramen ovale closure with the Intrasept occluder: complete 6-56 months follow-up of 247 patients after presumed paradoxical embolism. Catheter Cardiovasc Interv 2008;71:390-5.
5. Khairy P, O'Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med 2003;139:753-60.
6. Chessa M, Colombo C, Butera G, et al. Is it too early to recommend patent foramen ovale closure for all patients who suffer from migraine? A single-centre study. J Cardiovasc Med (Hagerstown). 2009;10:401-5.
7. Thaler DE, Saver JL. Cryptogenic stroke and patent foramen ovale. Curr Opin Cardiol 2008;23:537-44.
8. Thyssen JP, Menn T. Metal allergy: a review on exposures, penetration, genetics, prevalence, and clinical implications. Chem Res Toxicol 2010;23:309-18.
9. Jensen CS, Menné T, Lisby S, Kristiansen J, Veien NK. Experimental systemic contact dermatitis from nickel: a dose-response study. Contact Dermatitis 2003;49:124-32. (Pubitemid 38021662)
10. Nijhawan RI, Molenda M, Zirwas MJ, Jacob SE. Systemic contact dermatitis. Dermatol Clin 2009;27:355-64.
11. Kong H, Wilkinson JL, Coe JY, et al. Corrosive behaviour of Amplatzer devices in experimental and biological environments. Cardiol Young 2002;12:260-5. (Pubitemid 41238840)
12. Ries MW, Kampmann C, Rupprecht HJ, et al. Nickel release after implantation of the Amplatzer occluder. Am Heart J 2003;145:737-41. (Pubitemid 36403506)
13. Burian M, Neumann T, Weber M, et al. Nickel release, a possible indicator for the duration of antiplatelet treatment, from a nickel cardiac device in vivo: a study in patients with atrial septal defects implanted with an Amplatzer occluder. Int J Clin Pharmacol Ther 2006;44:107-12. (Pubitemid 43338010)
14. Wertman B, Azarbal B, Riedl M, Tobis J. Adverse events associated with nickel allergy in patients undergoing percutaneous atrial septal defect or patent foramen ovale closure. J Am Coll Cardiol 2006;47:1226-7.
15. NMT Medical announces preliminary results of CLOSURE I PFO/strokeTrial. Available at: http://www.snl.com/irweblinkx/file.aspx?IID=4148066&FID= 9712903. Accessed October 8, 2010.
16. Schwerzmann M, Windecker S, Wahl A, et al. Implantation of a second closure device in patients with residual shunt after percutaneous closure of patent foramen ovale. Catheter Cardiovasc Interv 2004;63:490-5.
17. Anzai H, Child J, Natterson B, et al. Incidence of thrombus formation on the CardioSEAL and the Amplatzer interatrial closure devices. Am J Cardiol 2004;93:426-31. (Pubitemid 38221349)
18. Krumsdorf U, Ostermayer S, Billinger K, et al. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol 2004;43:302-9. (Pubitemid 38201160)
19. Divekar A, Gaamangwe T, Shaikh N, Raabe M, Ducas J. Cardiac perforation after device closure of atrial septal defects with the Amplatzer septal occluder. J Am Coll Cardiol 2005;45:1213-8. (Pubitemid 40523139)
20. Trepels T, Zeplin H, Sievert H, et al. Cardiac perforation following transcatheter PFO closure. Catheter Cardiovasc Interv 2003;58:111-3. (Pubitemid 36055315)
21. Palma G, Rosapepe F, Vicchio M, et al. Late perforation of right atrium and aortic root after percutaneous closure of patent foramen ovale. J Thorac Cardiovasc Surg 2007;134:1054-5. (Pubitemid 47445631)
22. Cecconi M, Quarti A, Bianchini F, et al. Late cardiac perforation after transcatheter closure of patent foramen ovale. Ann Thorac Surg 2006;81:e29-30.
23. Lange SA, Schoen SP, Braun MU, et al. Perforation of aortic root as secondary complication after implantation of patent foramen ovale occlusion device in a 31-year-old woman. J Interv Cardiol 2006;19:166-9.